Protocol Ledger

NCT04047628 · Phase III · RECRUITING

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Interventional Phase III clinical trial protocol NCT04047628 sponsored by National Institute of Allergy and Infectious Diseases (NIAID) in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-08-17 Enrollment: 156 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04047628
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)156 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04047628
Protocol FieldVerified Registry Value
NCT IdentifierNCT04047628
Consolidated Lead SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment156 participants (ESTIMATED)
Registered Start Date2020-08-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI